Magnetic Fields / OS Cancer Research Results

MF, Magnetic Fields: Click to Expand ⟱
Features: Therapy
Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: OS↓">ROS, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Reactive oxygen species (ROS) ↑ ROS (P→R); often sustained (G) ↑ ROS (P); ↔/↓ net ROS (R→G) P, R, G Upstream redox perturbation MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2 NRF2 antioxidant response ↔ / insufficient NRF2 induction (R→G) ↑ NRF2 activation (R→G) R, G Adaptive redox defense Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3 Glutathione (GSH) homeostasis ↓ GSH (R→G) ↔ or transient ↓ (R) with recovery (G) R, G Redox buffering capacity GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4 Superoxide dismutase (SOD) / antioxidant enzymes ↔ or inadequate enzyme upshift (G) ↑ SOD/GPx/CAT capacity (G) G Longer-term antioxidant remodeling Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5 Mitochondrial ETC / respiration ↓ ETC efficiency; ↑ electron leak (P→R) ↔ mild, reversible ETC perturbation (P→R) P, R Bioenergetic destabilization ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6 Mitochondrial membrane potential (ΔΨm / MMP) ↓ ΔΨm (R); may progress (G) ↔ preserved or reversible dip (R) R, G Mitochondrial dysfunction thresholding ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7 Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux) ↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G) ↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G) P, R, G Stress signal amplification Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8 Mitochondrial permeability transition pore (MPTP) ↑ MPTP opening propensity (R); sustained opening possible (G) ↔ transient or closed (R→G) P, R, G Commitment point for mitochondrial failure MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9 ER stress / UPR ↑ ER stress (R); CHOP-commitment possible (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis stress Often downstream of ROS + Ca²⁺ handling perturbations
10 DNA damage (oxidative) ↑ damage markers (R→G) ↔ or repaired (G) R, G Checkpoint pressure Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11 LDH / glycolytic flux ↓ glycolytic performance (R→G) ↔ flexible substrate switching (R→G) R, G Metabolic vulnerability Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12 Thioredoxin system (Trx / TrxR) ↓ functional reserve / overload (R→G) ↔ preserved capacity (G) R, G Parallel antioxidant system stress Useful when GSH-only does not explain redox phenotype
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.


OS, overall survival: Click to Expand ⟱
Source:
Type:
Overall survival

Scientific Papers found: Click to Expand⟱
529- MF,    Low-frequency magnetic field therapy for glioblastoma: Current advances, mechanisms, challenges and future perspectives
- Review, GBM, NA
Ca+2↑, ROS↑, ChemoSen↑, QoL↑, OS↑,
2260- MF,    Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming
- in-vitro, GBM, U87MG - in-vitro, GBM, LN229 - in-vivo, NA, NA
TumCP↓, TumCG↓, OS↑, ROS↑, SOD2↑, eff↓, ECAR↓, OCR↑, selectivity↑, *toxicity∅, TumVol↓, PGC-1α↑, OXPHOS↑, Glycolysis↓, PKM2↓,
510- MF,    Effect of a 9 mT pulsed magnetic field on C3H/Bi female mice with mammary carcinoma. A comparison between the 12 Hz and the 460 Hz frequencies
- in-vivo, NA, NA
OS↑,
505- MF,    Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach
- Case Report, NA, NA
Pain↓, OS↑,
5534- MF,    Targeted Osmotic Lysis of Highly Invasive Breast Carcinomas Using Pulsed Magnetic Field Stimulation of Voltage-Gated Sodium Channels and Pharmacological Blockade of Sodium Pumps
- vitro+vivo, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumVol↓, VGSC↑, OS↑, selectivity↑, eff↑,
3499- MFrot,  MF,    Rotating magnetic field delays human umbilical vein endothelial cell aging and prolongs the lifespan of Caenorhabditis elegans
- in-vitro, Nor, HUVECs
*AntiAge↑, *AMPK↑, *mPGES-1↓, *Ca+2↑, *ER Stress↑, *OS↑, *ROS↓,
3493- MFrot,  MF,    Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes
- in-vivo, GBM, NA
TumCD↑, MMP↓, Cyt‑c↑, Apoptosis↑, OS↑, DNAdam↑,
2259- MFrot,  MF,    Method and apparatus for oncomagnetic treatment
- in-vitro, GBM, NA
MMP↓, Bcl-2↓, BAX↑, Bak↑, Cyt‑c↑, Casp3↑, Casp9↑, DNAdam↑, ROS↑, lactateProd↑, Apoptosis↑, MPT↑, *selectivity↑, eff↑, MMP↓, selectivity↑, TCA?, H2O2↑, eff↑, *antiOx↑, H2O2↑, eff↓, GSH/GSSG↓, *toxicity∅, OS↑,
2258- MFrot,  MF,    EXTH-68. ONCOMAGNETIC TREATMENT SELECTIVELY KILLS GLIOMA CANCER CELLS BY INDUCING OXIDATIVE STRESS AND DNA DAMAGE
- in-vitro, GBM, GBM - in-vitro, Nor, SVGp12
TumVol↓, OS↑, γH2AX↑, DNAdam↑, selectivity↑, ROS↑, TumCD↑, eff↑, eff↓,
205- MFrot,  MF,    Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis
- vitro+vivo, BC, MDA-MB-231
OS↑, F-actin↓, TumCI↓, TumCMig↓, Rho↓, selectivity↑, TumMeta↓,
198- MFrot,  MF,    Biological effects of rotating magnetic field: A review from 1969 to 2021
- Review, Var, NA
AntiCan↑, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, TumMeta↓, TumCCA↑, ETC↓, MMP↓, TumCD↑, selectivity↑, ROS↑, Casp3↑, TumCG↓, TumCCA↑, ChrMod↑, TumMeta↓, Imm↑, DCells↑, Akt↓, OS⇅, toxicity↓, QoL↑, hepatoP↑, Pain↓, Weight↑, Strength↑, Sleep↑, IL6↓, CD4+↑, CD8+↑, Ca+2↑, radioP↑, chemoP↑, *BMD↑, *AntiAge↑, *AMPK↑, *P21↓, *P53↓, *mTOR↓, *OS↑, *β-Endo↑, *5HT↓,
190- MFrot,  MF,  Chemo,    The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
- Human, Lung, NA
*IP-10/CXCL-10↑, *GM-CSF↑, *TREM-1↓, QoL↑, Ca+2↑, ROS↑, Apoptosis↑, OS↑,
224- MFrot,  MF,    A pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms
- Human, NSCLC, NA
PleEff↓, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, OS↑,
222- MFrot,  MF,    LF-MF inhibits iron metabolism and suppresses lung cancer through activation of P53-miR-34a-E2F1/E2F3 pathway
- in-vitro, Lung, A549
TumCG↓, OS↑, miR-34a↑, E2Fs↓, P53↑, TfR1/CD71↓, Ferritin↓,
221- MFrot,  MF,    Low Frequency Magnetic Fields Enhance Antitumor Immune Response against Mouse H22 Hepatocellular Carcinoma
- in-vivo, Liver, NA
OS↑, TumCG↓, IL6↓, GM-CSF↓, CXCc↓, Macrophages↑, DCells↑, CD4+↑, CD8+↑, IL12↑,
220- MFrot,  MF,    Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation
- in-vitro, Melanoma, B16-F10
OS↑, DCells↑, T-Cell↑, Apoptosis↑, IL1↑, IFN-γ↓, IL10↑, TumCG↓, ROS↑, TumCP↓, TumCCA↑, ChrMod↑, CXCL9↓, CXCL12↓, CD4+↑, CD8+↑,
217- MFrot,  MF,    Effect of low-frequency rotary magnetic fields on advanced gastric cancer
- in-vivo, GC, HL-60 - in-vivo, GC, SK-HEP-1
OS↑, Pain↓, ChemoSideEff↓, Weight↑, Strength↑, Sleep↑,

Showing Research Papers: 1 to 17 of 17

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 17

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

GSH/GSSG↓, 1,   H2O2↑, 2,   OXPHOS↑, 1,   ROS↑, 7,   SOD2↑, 1,  

Metal & Cofactor Biology

Ferritin↓, 1,   TfR1/CD71↓, 1,  

Mitochondria & Bioenergetics

ETC↓, 1,   MMP↓, 4,   MPT↑, 1,   OCR↑, 1,   PGC-1α↑, 1,   PleEff↓, 1,  

Core Metabolism/Glycolysis

ECAR↓, 1,   Glycolysis↓, 1,   lactateProd↑, 1,   PKM2↓, 1,   TCA?, 1,  

Cell Death

Akt↓, 1,   Apoptosis↑, 4,   Bak↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 2,   Casp9↑, 1,   Cyt‑c↑, 2,   TumCD↑, 3,  

Transcription & Epigenetics

BowelM↑, 2,   ChrMod↑, 2,  

DNA Damage & Repair

DNAdam↑, 3,   P53↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence

E2Fs↓, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State

miR-34a↑, 1,   TumCG↓, 5,   VGSC↑, 1,  

Migration

Ca+2↑, 3,   CXCL12↓, 1,   F-actin↓, 1,   Rho↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 2,   TumMeta↓, 3,  

Immune & Inflammatory Signaling

CD4+↑, 3,   CXCc↓, 1,   CXCL9↓, 1,   DCells↑, 3,   GM-CSF↓, 1,   IFN-γ↓, 1,   IL1↑, 1,   IL10↑, 1,   IL12↑, 1,   IL6↓, 2,   Imm↑, 1,   Macrophages↑, 1,   T-Cell↑, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 1,   eff↓, 3,   eff↑, 4,   selectivity↑, 6,  

Clinical Biomarkers

Ferritin↓, 1,   IL6↓, 2,  

Functional Outcomes

AntiCan↑, 1,   Appetite↑, 2,   breath↑, 2,   chemoP↑, 1,   ChemoSideEff↓, 1,   hepatoP↑, 1,   OS↑, 15,   OS⇅, 1,   Pain↓, 5,   QoL↑, 3,   radioP↑, 1,   Sleep↑, 2,   Strength↑, 4,   toxicity↓, 1,   TumVol↓, 3,   Weight↑, 2,  

Infection & Microbiome

CD8+↑, 3,  
Total Targets: 81

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis

AMPK↑, 2,  

Transcription & Epigenetics

TREM-1↓, 1,  

Protein Folding & ER Stress

ER Stress↑, 1,  

DNA Damage & Repair

P53↓, 1,  

Cell Cycle & Senescence

P21↓, 1,  

Proliferation, Differentiation & Cell State

mTOR↓, 1,  

Migration

Ca+2↑, 1,   β-Endo↑, 1,  

Immune & Inflammatory Signaling

GM-CSF↑, 1,   IP-10/CXCL-10↑, 1,   mPGES-1↓, 1,  

Synaptic & Neurotransmission

5HT↓, 1,  

Drug Metabolism & Resistance

selectivity↑, 1,  

Clinical Biomarkers

BMD↑, 1,  

Functional Outcomes

AntiAge↑, 2,   OS↑, 2,   toxicity∅, 2,  
Total Targets: 19

Scientific Paper Hit Count for: OS, overall survival
17 Magnetic Fields
12 Magnetic Field Rotating
1 Chemotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:172  Target#:229  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page